Frontlight ResearchEarly access
Liver and biliary tract cancer trials in Germany
45 of 56 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
- Where
- Magdeburg
- Age
- 18 years and over
- People
- 134 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00 - Phase 2Taking peopleVisugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
- Where
- Berlin, Cologne, Frankfurt Am Main, Freiburg im Breisgau, Hamburg, Hanover, Mainz, Ulm
- Age
- 18 years to 100 years
- People
- 104 worldwide
- Run by
- CatalYm GmbH
See details and how to joinNCT07219459 · EU 2025-520675-86-00 - No phaseTaking peopleTransarterial Chemoembolization (TACE) and Stereotactic Body Radiation (SBRT) in Patients With Hepatocellular Carcinoma (HCC) Prior to Liver Transplantation
- Where
- München
- Age
- 18 years and over
- People
- 44
- Run by
- AIO-Studien-gGmbH
See details and how to joinNCT07924943 - Phase 1Not yet taking people in GermanyA Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Where
- Essen
- Age
- 18 years and over
- People
- 340 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00 - Phase 2Not yet taking people in GermanyDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Frankfurt am Main, Giessen
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - Phase 1/2Taking peopleBOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
- Where
- Bonn, Ulm
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Bold Therapeutics, Inc.
See details and how to joinNCT04421820 · EU 2024-517500-11-00 - Phase 3Taking peopleEfficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Where
- Berlin, Dresden, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Hanover, Heidelberg, Luebeck, Munich, Tuebingen
- Age
- 18 years and over
- People
- 286 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT06282575 · EU 2023-508219-21-00 - Phase 1/2Taking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Berlin, Dresden, Heidelberg, Heilbronn, Leipzig, Mainz, Muenster
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - Phase 2Taking peopleDurvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma
- Where
- Aachen, Bonn, Cologne, Duesseldorf, Frankfurt am Main, Goettingen, Hanover, Luebeck, Mainz, Muenster
- Age
- 18 years and over
- People
- 42
- Run by
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
See details and how to joinNCT06440993 · EU 2023-509165-21-00 - Phase 1/2Taking peopleA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Where
- Cologne, Frankfurt Am Main, Luebeck, Mainz
- Age
- 18 years and over
- People
- 198 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07291076 · EU 2025-523602-33-00 - Phase 2Not yet taking people in GermanyEvaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
- Where
- Leipzig
- Age
- 18 years and over
- People
- 90 worldwide
- Run by
- Delcath Systems Inc.
See details and how to joinNCT06875128 · EU 2025-521966-91-00 - Phase 1/2Taking peopleA Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
- Where
- Bochum, München, Ulm
- Age
- 18 years and over
- People
- 245 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07186842 · EU 2025-522613-26-00 - Phase 3Taking peoplePhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Where
- Berlin, Bonn, Cologne, Dresden, Frankfurt am Main, Freiburg im Breisgau, Goettingen, Hamburg, Leipzig, Luebeck, Munich, Ulm, Wuerzburg
- Age
- 18 years to 99 years
- People
- 620 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06467357 · EU 2023-508057-19-00 - Phase 3Taking peoplePhase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Where
- Aachen, Berlin, Bonn, Chemnitz, Cologne, Dortmund, Dresden, Erlangen, Essen, Frankfurt am Main, Frankfurt Am Main, Hamburg, Hanover, Leipzig, Luebeck, Magdeburg, Moers, Munich, Ulm
- Age
- 18 years and over
- People
- 1,220 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06921785 · EU 2024-518210-81-00 - Phase 1/2CompletedSymbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Where
- Berlin, Bonn, Duesseldorf, Erlangen, Hanover, Mainz
- Age
- 18 years and over
- People
- 138 worldwide
- Run by
- Pfizer
See details and how to joinNCT07227012 · EU 2025-523525-17-00 - Phase 1/2Taking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Augsburg, Essen, Frankfurt am Main, Hamburg, Heidelberg
- Age
- 12 years and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - Phase 1Taking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Essen, Heidelberg, Herne, Jena, Nuertingen, Tuebingen
- Age
- 18 years and over
- People
- 1,394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - Phase 1Not yet taking people in GermanyA phase I, open-label, dose-escalation, safety, pharmacokinetic/-dynamic and clinical activity study of p38α inhibitor Skepinone-L to enhance therapeutic efficacy of Sorafenib in advanced hepatocellular carcinomas of non-viral origin
- Where
- Tuebingen
- Age
- 18 years and over
- People
- 20
- Run by
- Universitaetsklinikum Tuebingen AöR
See details and how to join2024-511516-24-00 - Phase 3Taking peopleA Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Where
- Aachen, Berlin, Bonn, Duesseldorf, Essen, Frankfurt am Main, Frankfurt Am Main, Freiburg im Breisgau, Hamburg, Heidelberg, Heilbronn, Karlsruhe, Magdeburg, Munich, Ulm
- Age
- 18 years and over
- People
- 1,100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07221253 · EU 2025-523085-24-00 - Phase 2WithdrawnStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Berlin, Essen, Hanover, München, Regensburg
- Age
- 18 years to 130 years
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - Phase 1/2Taking peopleSafety of HRX215 in Patients After Minor and Major Liver Resection
- Where
- Essen, Tübingen
- Age
- 18 years to 75 years
- People
- 80 worldwide
- Run by
- HepaRegeniX GmbH
See details and how to joinNCT06638502 - Phase 1Taking peoplePeptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA
- Where
- Tübingen
- Age
- 12 years and over
- People
- 20
- Run by
- University Hospital Tuebingen
See details and how to joinNCT06789198 · EU 2024-519387-41-00 - No phaseNot yet taking people in GermanyLiver Transplantation for Non-Resectable Colorectal Liver Metastases Without Local Treatment Options
- Where
- Berlin
- Age
- 18 years to 65 years
- People
- 260
- Run by
- Charite University, Berlin, Germany
See details and how to joinNCT07811453 - No phaseTaking peopleEndoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma
- Where
- Berlin, Bonn, Chemnitz, Essen, Hamburg, Hanover, Heidelberg, Lübeck, Ulm
- Age
- 18 years and over
- People
- 130
- Run by
- Universitätsklinikum Hamburg-Eppendorf
See details and how to joinNCT06175845 - Phase 3Taking peopleA Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR) altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)
- Where
- Frankfurt am Main, Hamburg, Hanover, Heidelberg, Munich, Reutlingen
- Age
- 18 years and over
- People
- 126 worldwide
- Run by
- Transthera Sciences (Nanjing) Inc.
See details and how to join2023-505660-11-00